Skip to main content

Table 1 Baseline characteristics of patients

From: Effect of bixalomer on coronary artery calcification in hemodialysis patients with hyperphosphatemia: a multi-center, randomized controlled trial

 

Total, N = 83

Bixalomer, n = 43

Calcium carbonate, n = 40

Concomitant treatment with lanthanum carbonate

28 (33.7)

15 (34.9)

13 (32.5)

Male sex

63 (75.9)

30 (69.8)

33 (82.5)

Age (years), mean ± SD

66.0 ± 9.8

66.0 ± 9.6

66.1 ± 10.1

Height (cm), mean ± SD

160.9 ± 7.1

159.9 ± 7.1

162.0 ± 7.2

Weight (kg), mean ± SD

57.3 ± 9.6

56.1 ± 9.1

58.5 ± 10.0

Underlying disease

 Diabetic nephropathy

28 (33.7)

15 (34.9)

13 (32.5)

 Chronic glomerulonephritis

16 (19.3)

8 (18.6)

8 (20.0)

 Nephrosclerosis

17 (20.5)

11 (25.6)

6 (15.0)

 Cystic kidney

4 (4.8)

0 (0.0)

4 (10.0)

 Chronic pyelonephritis

2 (2.4)

2 (4.7)

0 (0.0)

 Other

16 (19.3)

7 (16.3)

9 (22.5)

History of dialysis (years)

 < 1

8 (9.8)

3 (7.0)

5 (12.8)

 ≥ 1, < 5

29 (35.4)

13 (30.2)

16 (41.0)

 ≥ 5, < 10

21 (25.6)

14 (32.6)

7 (17.9)a

 ≥ 10, < 15

14 (17.1)

9 (20.9)

5 (12.8)

 ≥ 15

10 (12.2)

4 (9.3)

6 (15.4)

Method of dialysis

 Hemodialysis

69 (83.1)

35 (81.4)

34 (85.0)

 Hemodiafiltration

14 (16.9)

8 (18.6)

6 (15.0)

Dialysate calcium concentration (mEq/L)

 2.5

4 (4.8)

2 (4.7)

2 (5.0)

 2.75

11 (13.3)

4 (9.3)

7 (17.5)

 3.0

68 (81.9)

37 (86.0)

31 (77.5)

 Other

0 (0.0)

0 (0.0)

0 (0.0)

Complication

81 (97.6)

42 (97.7)

39 (97.5)

 High blood pressure

65 (78.3)

36 (83.7)

29 (72.5)

 Diabetes

29 (34.9)

16 (37.2)

13 (32.5)

 Anemia in CKDb

57 (68.7)

32 (74.4)

25 (62.5)

 Secondary hyperparathyroidism

33 (39.8)

16 (37.2)

17 (42.5)

 Constipation

30 (36.1)

19 (44.2)

11 (27.5)

 Itchy skin

15 (18.1)

8 (18.6)

7 (17.5)

 Other

51 (61.4)

28 (65.1)

23 (57.5)

Combination drug

73 (88.0)

39 (90.7)

34 (85.0)

 Antihypertensive

65 (78.3)

38 (88.4)

27 (67.5)

 Drug for osteoporosis

33 (39.8)

20 (46.5)

13 (32.5)

 Drug for dyslipidemia

21 (25.3)

11 (25.6)

10 (25.0)

No combination therapyc

80 (96.4)

41 (95.3)

39 (97.5)

  1. Data are presented as n (%) unless otherwise stated
  2. aThe number of patients specifically for dialysis history in the calcium group was 39 rather than 40, as there was one patient with missing data
  3. bAnemia in CKD is defined as hemoglobin level < 11.0 g/dL or erythropoietin use in patients with CKD
  4. cPatients not receiving any therapy other than that for hemodialysis or hemodiafiltration
  5. Abbreviations: CKD chronic kidney disease, SD standard deviation
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us